From: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Responders | Non-responders | |||||||
---|---|---|---|---|---|---|---|---|
Subset 1 | Subset 2 | Subset 1 | Subset 2 | |||||
Baseline | 3 monthsa | Baseline | 3 monthsa | Baseline | 3 monthsa | Baseline | 3 monthsa | |
Morning stiffness (minutes)b | 245 ± 126c | 35 ± 24.5c | 210 ± 81 | 58 ± 70.2c | 179 ± 159 | 66.4 ± 86c | 133 ± 84 | 62 ± 67.6c |
DAS28 b | 6.4 ± 1.0 | 4.2 ± 0.9c | 6.2 ± 0.7 | 3.8 ± 0.6c | 5.7 ± 0.8 | 5.3 ± 1.0 | 5.5 ± 1.0 | 4.9 ± 1.0c |
Pain (0–100 mm VAS) | 59.3 ± 20.3 | 29.3 ± 9.3c | 62.5 ± 15.5 | 31.3 ± 14.5c | 69.3 ± 13.1 | 54.1 ± 22.1 | 60.9 ± 11.4 | 40.6 ± 18.4c |
ESR (mm/hour) | 44 ± 26.2 | 27 ± 20.3c | 27.2 ± 15.7 | 11.3 ± 5.2c | 35.7 ± 25.7 | 28.3 ± 15.3 | 24.1 ± 11.5 | 27.8 ± 19.2 |
CRP (mg/l)b | 42 ± 29.8 | 20 ± 15.7c | 28.6 ± 19.7 | 6.2 ± 6.1c | 18.5 ± 12.7 | 13 ± 8.2 | 15.8 ± 15.6 | 11 ± 7.3 |
HAQ score (0–3 scale) | 1.6 ± 0.4 | 0.9 ± 0.5c | 1.8 ± 0.7 | 1.2 ± 0.7c | 1.6 ± 0.4 | 1.2 ± 0.3 | 1.5 ± 0.4 | 1.5 ± 0.4 |